Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will...
Additional US$5 million in Subscriptions to Close at a Later DateBOCA RATON, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jushi...
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development...
SCOTTSDALE, Ariz., Dec. 08, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of...
Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory ProgressHINGHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:...
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance...
Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney ExpansionCALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics...
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase...
Phase 2 clinical trial initiation expected in 2023Company to host conference call to discuss recent clinical updates, including updated data...
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company...
Oncology focused hospital to initiate Senhance System programRESEARCH TRIANGLE PARK, N.C., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc....
Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated...
Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host...
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast...
Data Presented at ESMO Immuno-Oncology CongressSOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT),...
Program trains people returning to the workforce for biotech manufacturing positionsLAUPHEIM, Germany and MILFORD, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE)...
Which data will inform more diverse clinical trials? Will healthcare influencers leave Twitter? How will engaging HCP thought leaders evolve?...
From Heart Failure to Kidney Disease, Patients with Chronic Conditions Will Automatically Inform Their Healthcare Provider About Treatment EfficacyBELLEVUE, Wash.,...